Li–Fraumeni Syndrome

Abstract

Li–Fraumeni syndrome (LFS) is a cancer predisposition syndrome caused by a germline mutation of the TP53 gene on chromosome 17p13.1. It has an autosomal dominant pattern of inheritance with high penetrance. These patients have a very high lifetime cumulative risk of developing multiple malignancies and have a strong family history of early-onset malignancies. The protein p53, encoded by TP53, has a complex set of genome-preserving functions initiated during episodes of cellular stress and DNA damage. In LFS, TP53 gene mutations cause the loss of function of p53, leading to downstream events permissive for development of various malignancies throughout life. The LFS component tumors include soft tissue sarcomas, osteosarcoma, premenopausal breast cancer, brain tumors, and adrenal cortical carcinomas. Multiple types of sarcomas have been reported in association with LFS; this review article will focus on the most frequently encountered pediatric sarcomas associated with TP53 mutations.

Keywords

Li–Fraumeni syndrome - TP53 - p53 - rhabdomyosarcoma - osteosarcoma

• References

• 1 Li FP, Fraumeni Jr JF. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome?. Ann Intern Med 1969; 71 (4) 747-752
• 2 Birch JM, Hartley AL, Marsden HB, Harris M, Swindell R. Excess risk of breast cancer in the mothers of children with soft tissue sarcomas. Br J Cancer 1984; 49 (3) 325-331
• 3 Li FP, Fraumeni Jr JF, Mulvihill JJ , et al. A cancer family syndrome in twenty-four kindreds. Cancer Res 1988; 48 (18) 5358-5362
• 4 Birch JM, Hartley AL, Blair V , et al. Identification of factors associated with high breast cancer risk in the mothers of children with soft tissue sarcoma. J Clin Oncol 1990; 8 (4) 583-590
• 5 Lustbader ED, Williams WR, Bondy ML, Strom S, Strong LC. Segregation analysis of cancer in families of childhood soft-tissue-sarcoma patients. Am J Hum Genet 1992; 51 (2) 344-356
• 6 Malkin D, Li FP, Strong LC , et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250 (4985) 1233-1238
• 7 Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 1990; 348 (6303) 747-749
• 8 Varley J, Haber DA. Familial breast cancer and the hCHK2 1100delC mutation: assessing cancer risk. Breast Cancer Res 2003; 5 (3) 123-125
• 9 Pinto EM, Ribeiro RC, Figueiredo BC, Zambetti GP. TP53-associated pediatric malignancies. Genes Cancer 2011; 2 (4) 485-490
• 10 Pflaum J, Schlosser S, Müller M. p53 family and cellular stress responses in cancer. Front Oncol 2014; 4: 285
• 11 Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer 2009; 9 (10) 749-758
• 12 Lane DP. Cancer. p53, guardian of the genome. Nature 1992; 358 (6381) 15-16
• 13 Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408 (6810) 307-310
• 14 Blattner C, Hay T, Meek DW, Lane DP. Hypophosphorylation of Mdm2 augments p53 stability. Mol Cell Biol 2002; 22 (17) 6170-6182
• 15 Bell DW, Varley JM, Szydlo TE , et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999; 286 (5449) 2528-2531
• 16 Gonzalez KD, Noltner KA, Buzin CH , et al. Beyond Li Fraumeni syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 2009; 27 (8) 1250-1256
• 17 Eeles RA. Germline mutations in the TP53 gene. Cancer Surv 1995; 25 (25) 101-124
• 18 Kamihara J, Rana HQ, Garber JE. Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome. Hum Mutat 2014; 35 (6) 654-662
• 19 Chompret A, Abel A, Stoppa-Lyonnet D , et al. Sensitivity and predictive value of criteria for p53 germline mutation screening. J Med Genet 2001; 38 (1) 43-47
• 20 Kleihues P, Schäuble B, zur Hausen A, Estève J, Ohgaki H. Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol 1997; 150 (1) 1-13
• 21 Qualman SJ, Coffin CM, Newton WA , et al. Intergroup Rhabdomyosarcoma Study: update for pathologists. Pediatr Dev Pathol 1998; 1 (6) 550-561
• 22 Fletcher CDM. Soft tissue tumors. In: Fletcher CDM, ed. Diagnostic Histopathology of Tumors. 3rd ed. China: Churchill Livingstone Elsevier; 2007: 1527-1592
• 23 Gurney JG, Davis S, Severson RK, Fang JY, Ross JA, Robison LL. Trends in cancer incidence among children in the U.S. Cancer 1996; 78 (3) 532-541
• 24 Ognjanovic S, Linabery AM, Charbonneau B, Ross JA. Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975-2005. Cancer 2009; 115 (18) 4218-4226
• 25 Parham D, Barr FG, Montgomery EA, Nascimiento AF. Skeletal-muscle tumours. In: Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, eds. WHO Classification of Tumours of Soft Tissue and Bone. Lyon: International Agency for Research on Cancer; 2013: 123-135
• 26 Parham DM, Barr FG. Classification of rhabdomyosarcoma and its molecular basis. Adv Anat Pathol 2013; 20 (6) 387-397
• 27 Hettmer S, Archer NM, Somers GR , et al. Anaplastic rhabdomyosarcoma in TP53 germline mutation carriers. Cancer 2014; 120 (7) 1068-1075
• 28 Parham DM, Qualman SJ, Teot L , et al; Soft Tissue Sarcoma Committee of the Children's Oncology Group. Correlation between histology and PAX/FKHR fusion status in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group. Am J Surg Pathol 2007; 31 (6) 895-901
• 29 Chen L, Shern JF, Wei JS , et al. Clonality and evolutionary history of rhabdomyosarcoma. PLoS Genet 2015; 11 (3) e1005075
• 30 Seki M, Nishimura R, Yoshida K , et al. Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma. Nat Commun 2015; 6: 7557
• 31 Unni KK, Inwards CY. Tumors of the osteoarticular system. In: Fletcher CDM, ed. Diagnostic Histopathology of Tumors. 3rd ed. China: Churchill Livingstone Elsevier; 2007: 1593-1652
• 32 Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 2009; 115 (7) 1531-1543
• 33 Rosenberg AE, Cleton-Jansen A-M, de Pinieux G, Deyrup AT, Hauben E, Squire J. Conventional osteosarcoma. In: Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, eds. WHO Classification of Tumours of Soft Tissue and Bone. Lyon: International Agency for Research on Cancer; 2013: 282-288
• 34 Selvarajah S, Yoshimoto M, Ludkovski O , et al. Genomic signatures of chromosomal instability and osteosarcoma progression detected by high resolution array CGH and interphase FISH. Cytogenet Genome Res 2008; 122 (1) 5-15
• 35 Martin JW, Squire JA, Zielenska M. The genetics of osteosarcoma. Sarcoma 2012; 2012: 627254
• 36 Mirabello L, Yeager M, Mai PL , et al. Germline TP53 variants and susceptibility to osteosarcoma. J Natl Cancer Inst 2015; 107 (7) djv101